A lifestyle disease improving drug is disclosed that enhances PPARα, δ and γ agonist activities that includes a compound having the lactone structure in accordance with the chemical formula 6-alkyl-5,6-dihydro-2H-pyran-2-one, the alkyl containing 4, 5, or 6 carbons. Methods for enhancing PPARα, γ and δ agonist activities in vertebrates or medically treating a vertebrate are disclosed. The methods include providing a composition of an active ingredient, the lifestyle disease improving drug, in a biologically acceptable medium and administering an effective amount of the composition to a vertebrate.
